title: IL-17 mediates resistance to anti-VEGF therapy.
abstract: Interleukin-17 (IL-17) released in the tumor microenvironment in response to drugs blocking vascular endothelial growth factor (VEGF) triggers stromal-derived inflammatory and VEGF-independent angiogenic programs that induce the drug refractoriness found in cancers resistant to anti-angiogenic therapy.
authors.affiliation: Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, UK.
authors.forename: Eleni
authors.initials: E
authors.lastname: Maniati
authors.forename: Thorsten
authors.initials: T
authors.lastname: Hagemann
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism*; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology*; D058504:Th17 Cells / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D020381:Interleukin-17; D042461:Vascular Endothelial Growth Factor A; C467480:vascular endothelial growth factor A, mouse